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Background: Inflammatory cytokines such as interleukin-1 beta (IL-1β) contribute to the progression of intervertebral
disc degeneration. Previously we demonstrated, in vitro, that by delivering interleukin-1 receptor antagonist (IL-1ra)
from poly(lactic co-glycolic acid) (PLGA) microspheres, we could attenuate the degradative effects of IL-1β on the
nucleus pulposus (NP) for up to 20 days. The objective of this study was to undertake a preliminary investigation into
whether microspheres could be successfully delivered to and retained in the disc in vivo, and whether IL-1ra released
from those microspheres remained biologically active. For retention studies, fluorescently-labeled microspheres were
delivered to the NPs of rat caudal discs. Rats were sacrificed at time points up to 56 days, and microspheres were localized
using fluorescent microscopy. To investigate whether IL-1ra microspheres could effectively inhibit the effects of IL-1β
in vivo, four disc levels were allocated to the following treatment groups: intact; saline; IL-1β; or IL-1β + IL-1ra microspheres.
Rats were sacrificed after seven days and NP glycosaminoglycan content was measured.
Findings: Microspheres were visible in the disc at all time points up to 28 days, and localized to the NP, the annulus
fibrosus (AF), or both. Glycosaminoglycan content for discs injected with IL-1β alone was significantly lower than for intact
controls. For discs injected with IL-1β along with IL-1ra microspheres, glycosaminoglycan content was not significantly
different from intact controls.
Conclusions: Microspheres can successfully be delivered to the disc in vivo and retained for a clinically relevant time
frame. IL-1ra released from microspheres can effectively prevent IL-1β-induced NP glycosaminoglycan loss in vivo.
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In vivoIntroduction
Intervertebral disc degeneration is a cascade beginning
with changes to the local cellular microenvironment and
progressing over years to structural breakdown and
functional impairment [1,2]. Changes to the central
nucleus pulposus (NP) are implicated in the early stages
of disc degeneration, where decreasing proteoglycan* Correspondence: lachlans@mail.med.upenn.edu
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sure impair the ability of the disc to evenly distribute
and transfer compressive loads between the vertebrae
[3]. Inflammation plays a key role in the progression of
disc degeneration. Interleukin-1 beta (IL-1β), in particu-
lar, is more highly expressed in the degenerate NP than
in the healthy NP [4]. Elevated IL-1β induces catabolic
protease activity, which degrades the disc extracellular
matrix and contributes to structural failure [5].
Interleukin-1 receptor antagonist (IL-1ra) is an endogen-
ous inhibitor of IL-1β, where it acts by competitively block-
ing the binding of IL-1β to receptors on IL-1 responsive
cells [6]. While IL-1β is upregulated with disc degener-
ation, there is no concomitant upregulation of IL-1ra [4],Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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signaling. In our previous in vitro work, we demonstrated
that soluble IL-1ra effectively inhibited the degradative ef-
fects of IL-1β on NP cells [7]. Further, by delivering IL-1ra
from poly(lactic-co-glycolic acid) (PLGA) microspheres, in-
hibition could be maintained for up to 20 days [8]. Key ad-
vantages of PLGA microspheres for drug delivery include
that they are biodegradable and biocompatible, already
FDA approved for other clinical indications, and most im-
portantly, can be easily tuned to alter degradation and pro-
tein release kinetics [9,10].
The objective of this study was to advance this encour-
aging in vitro work to towards clinical translation, by
undertaking a preliminary in vivo study to demonstrate,
firstly, that PLGA microspheres could be delivered to the
disc and retained for a clinically relevant time frame
in vivo; and, secondly, that IL-1ra delivered from these mi-
crospheres maintained bioactivity in the in vivo space.
Materials and methods
Microsphere fabrication
PLGA microspheres were fabricated as described previ-
ously, using the water/oil/water double emulsion technique
[8,9]. As in our previous work, we used the pharmaceutical
form of IL-1ra, anakinra (Amgen, Thousand Oaks, CA).
The initial water/oil emulsion was formed by combining
225μL of IL-1ra (0.15 g/ml) with 1 ml of 75:25 PLGA (0.1
g/ml) (Durect Corporation, Pelham, AL). For fluorescent
microsphere studies, the PLGA was supplemented with
3 mg/ml coumarin-6 (Sigma Aldrich; λemission =505 nm;
λabsorption =444 nm), and saline was substituted for IL-
1ra. Fabricated microspheres were lyophilized until
required for surgeries, and sterilized via exposure to
ultraviolet light for 10 min prior to injection. The
release profile of IL-1ra from these microspheres was
described previously, and is characterized by an initial
burst release, decreasing to an approximately linear and
sustained release over the initial 10 days. In vitro, bioactive
IL-1ra continues to be released for up to 20 days [8].
In vivo microsphere retention study
The Animal Studies Subcommittee of the Philadelphia
VA Medical Center approved all animal studies. We first
performed a study to confirm that microspheres could
be successfully delivered to the rat caudal intervertebral
disc, and retained for a clinically relevant time period.
Six, male, retired breeder, Sprague-Dawley rats aged 8
months were anesthetized via isoflurane inhalation. Caudal
disc levels for injection (C7-8, C8-9 and C9-10) were identi-
fied fluoroscopically (Orthoscan HD; Orthoscan, Scottsdale,
USA) by counting spine levels caudally from the sacrum.
Each disc was exposed via a 5 mm dorsal incision through
the skin. Under fluoroscopic guidance, fluorescent micro-
spheres (20 mg/ml in sterile saline, total volume 1.5 μl)were injected into the NP of each of the three disc levels
using custom 33-gauge needles designed to restrict the
depth of needle insertion to 2.5mm (Figures 1A and B).
Each injection was performed carefully over the course of
2-3 s. Animals were euthanized via carbon dioxide inhal-
ation at each of 6 time points post-surgery: 1, 3, 7, 14, 28
and 56 days. Following euthanasia, spine segments contain-
ing injected discs were isolated from the tail by bisecting
the adjacent vertebral bodies. These segments were snap
frozen and sectioned (undecalcified) progressively through
the vertebral bone on a cryostat microtome in the trans-
verse plane until the disc was exposed. Sections 20 μm
thick were then obtained through the entire thickness of
the disc, and captured on glass microscope slides. Sections
were immediately imaged on a fluorescence microscope
(Eclipse 90i; Nikon, Tokyo, Japan) to determine the pres-
ence or absence of microspheres, and their location in the
disc (NP or annulus fibrosus (AF)) by overlaying fluores-
cence images on differential interference contrast (DIC)
images of the same region.
In vivo bioactivity study
Next, we performed a study to confirm the in vivo bio-
activity of IL-1ra microspheres delivered to the rat NP.
Four caudal disc levels per animal were utilized (C7-8, C8-
9, C9-10 and C10-11), and randomly allocated to one of
four study groups: intact (non-injected) controls; sham
(vehicle only) injection; IL-1β injection; or IL-1β + IL-1ra
microspheres (20 mg/ml) injection. The study was per-
formed for each of two IL-1β doses: 100 ng and 500 ng
(each n = 4 animals). All injection volumes were 1.5 μl
with sterile saline as the vehicle, delivered using modified
33-gauge needles. Surgeries were performed as described
above. All animals were euthanized 7 days post-surgery.
Following euthanasia, spine segments containing injected
or control discs were isolated, and NP regions analyzed
for GAG content. To overcome the challenges associated
with accurate determination of GAG content in very small
tissue specimens, we developed a dissection technique to
accurately isolate NP samples of known volume. Spine
segments were snap frozen and mounted in a cryostat
microtome. Sections of vertebral bone were progressively
removed until the transverse face of the disc was exposed.
Four 100 μm-thick sections of disc were then cut and
transferred, frozen, to a glass microscope slide. A 1 mm
biopsy punch was then used to isolate the NP from the
AF. Isolated NP samples were then digested in papain and
assayed to determine total sulfated GAG content
(expressed as absolute GAG per sample) using the
dimethylmethylene blue technique [11]. Differences in
GAG content between groups were established using
ANOVAs followed by post-hoc, pairwise Tukey’s tests. Re-
sults were expressed as mean ± standard deviation, with
significance defined as p < 0.05.
Figure 1 In vivo delivery and localization microspheres. A. Delivery of microspheres to the rat NP from a custom 33-gauge needle under fluoroscopic
guidance (lateral aspect). B. Higher magnification view of A. C. Differential interference contrast (DIC), axial image of entire disc 1 day post injection,
showing NP and AF regions. D. Higher magnification view of the AF (inset from C.) showing microspheres (red). E. Microspheres (red, overlaying DIC
image) embedded in the inner lamellae of the AF. F. Differential interference contrast, axial image of entire disc 14 days post injection, showing NP and AF
regions. G. Higher magnification view (inset from F.) showing microspheres (red). H. Microspheres (red, overlaying DIC image), embedded in the NP.
Figure 2 In vivo bioactivity of microspheres. IL-1β injection alone
resulted in a significantly lower NP GAG content compared to intact
controls. For the combined IL-1β and IL-1ra microspheres injection,
NP GAG content was not significantly different from intact controls.
For the saline sham injection, NP GAG content was lower than intact
controls, but not significantly, and not significantly different from
IL-1β alone or combined IL-1β and IL-1ra microspheres. *p < 0.05 vs.
intact controls; +p < 0.05 vs. IL-1β alone.
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In vivo retention of microspheres
To determine whether microspheres could be success-
fully delivered to the rat disc and retained for a clinically
relevant time frame, fluorescent microspheres were
injected into rat caudal discs, and their presence or
absence and localization (AF or NP) investigated at six
post-surgical timepoints up to 8 weeks. Fluorescence
microscopy confirmed the presence of microspheres in
all discs and at all time points up to 28 days post-
surgery. In discs where microspheres were present, their
localization varied between the AF only (63% of discs,
Figures 1C-E), the NP only (13% of discs, Figures 1F-H),
or both the NP and the AF (25% of discs). There was no
apparent association between time point and location
of microspheres in the disc. Cryostat sections were
also examined for evidence of microsphere leakage
along the injection track, but no such leakage was
observed.
In vivo bioactivity of IL-1ra microspheres
To confirm that the bioactivity of IL-1ra released from
microspheres was maintained following in vivo delivery,
we investigated the efficacy of IL-1ra microspheres in
mitigating GAG loss induced by injection of exogenous
IL-1β into rat caudal discs. No statistically significanteffect of IL-1β dosage (100 ng or 500 ng) on GAG con-
tent was found, so results for both dosages were pooled
for subsequent analyses. IL-1β injection alone (Figure 2),
resulted in a significantly lower NP GAG content com-
pared to intact controls (65% of intact, p < 0.05). For the
combined IL-1β and IL-1ra microspheres injection, NP
GAG content was maintained, and not significantly dif-
ferent from intact controls (102% of intact, p > 0.05). For
the saline sham injection, NP GAG content was lower
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cantly different from IL-1β alone or combined IL-1β and
IL-1ra microspheres.Discussion and conclusions
IL-1ra has successfully been used clinically for the treat-
ment of rheumatoid arthritis for a number of years [12],
and has recently been investigated as a potential treatment
for osteoarthritis [13]. In previous work we demonstrated
that soluble IL-1ra can effectively inhibit the degradative
effects of IL-1β on the NP at the mechanical, compos-
itional and molecular levels [7]. Another study showed
that IL-1ra delivered both directly in solution and by gene
therapy inhibited mRNA expression and activity of cata-
bolic enzymes upregulated by IL-1β in disc tissue explants
[14]. Further, IL-1ra knockout mice exhibit degenerative
changes consistent with human disc degeneration [15].
The avascular nature of the disc, along with the short
half-life and required high therapeutic concentrations of
IL-1ra [16], suggest that in vivo, systemic delivery for
treatment of disc degeneration is unlikely to be successful.
Repeated intradiscal injections of IL-1ra that would be
necessary to sustain high local concentrations, are imprac-
tical and may induce further degenerative changes via
structural damage to the AF resulting from repetitive
delivery. Therefore, to enhance the therapeutic efficacy of
IL-1ra for treating disc degeneration, we developed a sus-
tained release delivery vehicle for IL-1ra. Using biodegrad-
able PLGA microspheres, we demonstrated previously
that, in vitro, we could inhibit the degradative effects of
IL-1β on the NP for up to 20 days. Building on these
results, in this study we demonstrated that PLGA micro-
spheres can be delivered to the disc in vivo and be
retained for up to 28 days. Importantly, retention time in
the disc (analogous to the time it takes for microspheres
to fully degrade), is longer than the time period over
which microspheres continue to release active IL-1ra at
therapeutic concentrations [8]. In our microsphere reten-
tion study, variability was apparent with respect to the lo-
cation of microspheres in the disc (NP, AF or both). One
possible explanation for this is that, with time, micro-
spheres diffuse away from the NP towards the AF where
they are caught in the dense, fibrocartilaginous lamellae.
However, as there was no apparent association between
time point and location of microspheres in the disc, a
more likely explanation may have been minor inconsisten-
cies in injection location. We hypothesize that active IL-
1ra released from microspheres is likely to diffuse
throughout the entire disc structure, irrespective of the lo-
cation of microspheres. The results of the in vivo bioactiv-
ity study reported here support this contention: IL-1ra
microspheres successfully inhibited NP GAG loss induced
by IL-1β.This study represents a preliminary investigation into
the in vivo efficacy of using anti-inflammatory micro-
spheres in the intervertebral disc, and is not without lim-
itations. Additional study groups should be investigated as
part of future work, such as injection of blank (non-IL-1ra
loaded) microspheres, specifically to determine if acidic
microsphere degradation products exert any inflammatory
effect. Clearance of these degradation products must
occur via passive diffusion to vasculature outside the NP.
Our previous in vitro work suggests that any such effects
are likely quite mild [8]. Future studies should also con-
firm that these microspheres are active for long periods
in vivo, in the presence of chronic inflammation, and are
more effective under such circumstances than a single,
bolus injection of IL-1ra. The small sample size was an
addition limitation of this study, although it was sufficient
to detect significant changes in GAG content.
Attenuation of inflammation in the degenerate disc is
only one component of a potential biological therapy for
disc degeneration. A stem cell-based component may be
required to potentiate tissue regeneration. In addition to
preventing further degenerative changes, IL-1ra micro-
spheres may foster a microenvironment that is anti-
inflammatory and more conducive to stem cell survival,
differentiation and biosynthesis [17]. Pursuant to the en-
couraging findings reported here, we are now designing
combined anti-inflammatory and stem cell-based thera-
peutics for disc regeneration and evaluating their efficacy
in large animal models.
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